ライフサイエンスコーパス: nontreated

1 ine bone density, femurs were collected from nontreated, 1,25-dihydroxyvitamin D3-treated (50 ng/mous

2 s for treated (1905 mm(-6)/sec2 +/- 446) and nontreated (1437 mm(-6)/sec2 +/- 270) fibroid tissue at

3 MM when treated with VBMCP (treated, 47.1% v nontreated, 66.5% [P = .015]).

4 cantly more susceptible to Ad infection than nontreated A20 cells.

5 amyloid burden, respectively, compared with nontreated AD mice.

6 period, but remained elevated compared with nontreated adoptive transfer mice.

7 t age-related cognitive decline displayed in nontreated aged animals.

8 All nontreated allografts rejected within 5 to 8 days posttr

9 ns in the oxidation of ICHO to ICOOH in both nontreated and AgNO3-treated leaves, whereas CYP71B6 is

10 Groups of nontreated and CFA-preimmunized male C57BL/6J or C57BL/6

11 this cell line and further characterizes the nontreated and induced myocardial and endothelial phenot

12 nd hepatic microcirculation were compared in nontreated and interleukin-6 (IL-6)-treated steatotic is

13 ls entered the CNS in numbers equivalent for nontreated and PLP(139-151) MAP-treated animals.

14 d metabolite profiling, their composition in nontreated and silver nitrate (AgNO3)-treated leaf tissu

15 + xenografts to approximately 30% of that in nontreated animals (from 34 +/- 9 [mean +/- SD] to 9.5 +

16 d ED1(+) macrophages (-52%) that occurred in nontreated animals after 6 hours of reloading.

17 ration, and ascites volume, were observed in nontreated animals and were significantly diminished by

18 ered to rats at 500, 50, 5, and 0.5 mg/kg/d; nontreated animals were used as controls.

19 Nontreated animals were used as the control (Group 1, n=

20 PVBF, 79% of baseline vs. 45% of baseline in nontreated animals, P < 0.05, ANOVA).

21 -cell depletion were similar for treated and nontreated animals.

22 fter AAD, 48% underwent surgery of initially nontreated aortic segments (42% of patients with type A

23 thout AAD, 11% required surgery on primarily nontreated aortic segments (5 of 6 patients experienced

24 auses of surgical interventions in primarily nontreated aortic segments after previous aortic repair

25 The need for surgery in primarily nontreated aortic segments is precipitated by an initial

26 In addition, the nontreated area showed amplitude and timing mfERG defici

27 In comparison with nontreated asthmatic mice, we observed that: (i) The bet

28 sured fluorescence intensity for treated and nontreated beads.

29 s was correlated with the DN:P ratio for the nontreated brain tumor group (P < .0001).

30 oup demonstrated higher DN:P ratios than the nontreated brain tumor group for number of doses less th

31 ual to 10 (P < .0001), whereas ratios in the nontreated brain tumor group were higher than those in t

32 eated C57BL/6 Ly5.2 BM cells were mixed with nontreated C57BL/6 Ly5.1 BM cells and used to reconstitu

33 ks in diazoxide-treated hearts compared with nontreated Ca2+ PD hearts.

34 tably, we show that these mutations occur in nontreated cancer cell lines and primary tumor specimens

35 se-treated xenografts was much lower than in nontreated cartilage and the proportion of T lymphocytes

36 eline to 24 h, was greater in treated versus nontreated cases (p < 0.001).

37 L-1betaAb-treated CDs-HSD rats compared with nontreated CDs-HSD rats.

38 01) and higher GSIS (P < 0.05) compared with nontreated CDs-HSD rats.

39 germ agglutinin affinity chromatography from nontreated cells exhibited substantial ligand-induced ph

40 nobufagenin levels by 67% when compared with nontreated cells or cells transfected with nontargeting

41 enhancer, and no DNA looping was observed in nontreated cells or cells treated with each of the hormo

42 inocytes compared with the results seen with nontreated cells or cells treated with glutathione S-tra

43 Nontreated cells were used as controls.

44 Mixing of extract from nontreated cells with small amounts of extract of CPT-tr

45 nd altered ultrastructure in comparison with nontreated cells, whereas copper overload has the opposi

46 tors on rapamycin-treated HuH7 cells than on nontreated cells, with no affect on the level of surface

47 reporter gene activity was still present in nontreated cells.

48 ranscripts to approximately 13% of levels in nontreated cells.

49 d EGFR kinase activity to levels observed in nontreated cells.

50 as not significantly different from that for nontreated cells.

51 lacZ expression to less than 25% of that of nontreated cells.

52 is, and viral RNA accumulation compared with nontreated cells.

53 t blunting of mediator release compared with nontreated cells.

54 her uptake of (64)Cu-bis-DOTA-hypericin than nontreated cells.

55 resulted in increased virus load compared to nontreated chickens.

56 experimental groups were evaluated: control (nontreated) clots, clots treated with pulsed high-intens

57 When compared with a nontreated cohort, OLT recipients receiving combination

58 vival of xenografted mice in comparison with nontreated control animals, but the effects were less pr

59 8-20, pair-fed dams injected with saline, or nontreated control dams.

60 ochloride daily on gestational Days 8-20 and nontreated control dams.

61 dine or PBS treatment when compared with the nontreated control group.

62 5.83%, P=0.035) hearts compared with that in nontreated control hearts (84.85%).

63 increased its local population compared with nontreated control muscles.

64 njured, nontreated controls (sham), injured, nontreated controls (control), or injured animals treate

65 and markedly reduced mortality compared with nontreated controls (four of five animals survived in a

66 imals were allocated to either sham-injured, nontreated controls (sham), injured, nontreated controls

67 tiangiogenic drugs alone survived, while all nontreated controls and tumor vaccine-treated rats died

68 Intubated sham control and nontreated controls were included.

69 ed GBS vaginal colonization in comparison to nontreated controls, and this effect was partially depen

70 PGE(2), compared with nontreated controls, increased expression and activity (

71 cantly reduced tumor volume in comparison to nontreated controls, increased survival, and prevented t

72 umor volume was calculated and compared with nontreated controls.

73 ease in tumor growth rate in comparison with nontreated controls.

74 that was comparable with that of tumor-free nontreated controls.

75 d hypertrophic by treatment with PHE than in nontreated controls.

76 nly detected after NGF treatment, but not in nontreated controls.

77 le their diffusion was completely blocked in nontreated controls.

78 roups: treatment with ranolazine, GS-967, or nontreated controls.

79 nesis with a fourfold increase compared with nontreated controls.

80 e treated diabetic animals compared with the nontreated diabetic controls.

81 ated diabetic PB-MNCs versus those receiving nontreated diabetic PB-MNCs.

82 on, which was increased two-fold compared to nontreated diabetic rats.

83 ited significantly greater SGC survival than nontreated ears.

84 tion, we compared oxygen-deprived embryos to nontreated embryos in both wild-type and hif-1 mutants.

85 ctors or tumor cells induced angiogenesis in nontreated embryos, further indicating a direct proangio

86 e ablation with 0.02% MMC were compared with nontreated eyes at Vissum Santa Hortensia, Madrid, Spain

87 er RLB, aqueous humor samples harvested from nontreated eyes but not from either the burned or the co

88 ulated by the comparison between treated and nontreated eyes in the same mouse.

89 ng ability was measured at two visits in 124 nontreated eyes of 124 patients with AMD, who were enrol

90 s was observed on edges of human TM beams in nontreated eyes, with intense staining in the juxtacanal

91 or IOP were detected between IPH-treated and nontreated eyes.

92 Control data were obtained from the nontreated fellow eyes, 24 normal monkeys, and 19 monkey

93 Posttreatment ADC values for nontreated fibroid tissue (1685 mm(-6)/sec2 +/- 468) dif

94 months were compared with volume changes in nontreated fibroids and with MR-based thermal dose estim

95 ced mobility by SDS-PAGE compared to that of nontreated filaments.

96 eater viability than B cells cocultured with nontreated FLS.

97 come versus 255 of 422 patients (63%) in the nontreated group (p < 0.001).

98 wer subbasal nerves number compared with the nontreated group (P = 0.01).

99 roup and 0.032 episodes/patient-month in the nontreated group (p = 0.04).

100 roup and 0.012 episodes/patient-month in the nontreated group (p = 0.05).

101 roup and 0.035 episodes/patient-month in the nontreated group (p = 0.56).

102 roup and 0.029 episodes/patient-month in the nontreated group (p = 0.64).

103 group and 67% and 41 %, respectively, in the nontreated group (p = 0.77).

104 choroidal thickness than the patients in the nontreated group after adjusting for age, axial length,

105 The nontreated group exhibited persistent endogenous glucose

106 and 73 (65%) received no additional therapy (nontreated group).

107 ssed ROP who had not received any treatment (nontreated group).

108 d animals viral load was 2.58 +/- 1.0 in the nontreated group, 4.74 +/- 1.38 in the group treated wit

109 ues during the endotoxic phase (P < 0.05 vs. nontreated group, ANOVA).

110 O2 (140% and 79%, respectively; P < 0.05 vs. nontreated group, ANOVA).

111 remained within baseline range (P < 0.05 vs. nontreated group, ANOVA).

112 and GC were markedly lower compared with the nontreated group.

113 ficantly lower incidence of infection in the nontreated group.

114 in the treated group and 17.8 months in the nontreated group.

115 used to achieve comparability of treated and nontreated groups in terms of their observed covariates

116 genation group, whereas the sham-treated and nontreated groups showed retinal thinning and choroidal

117 NV in the ribavirin-treated (100 microM) and nontreated groups showed that the mutation rates were si

118 mol/mL and < 6.0 mumol/mL in the treated and nontreated groups, respectively) and reduced tPA levels

119 Four nontreated healthy rats served as controls.

120 p analysis of mRNA from IL-1beta-treated and nontreated HS-27a cells has identified some candidate mo

121 ntent (0.79 +/- 0.05 mumol/g, P < .01 versus nontreated hypercholesterolemic rabbits), restored the v

122 postinfection (p.i.) compared to results for nontreated, infected mice.

123 Control mice were transplanted with nontreated islets and were injected with saline.

124 Compared with nontreated islets, the combination of KIC/glutamine (10/

125 the relative (ratio of treated kidney value/nontreated kidney value) clearance of small- and large-m

126 formed in 16 hormone-treated patients and 48 nontreated matched control patients before radical prost

127 in brain was found in comparison to that in nontreated mice (n = 3, P < 0.05).

128 nificantly (P = .0001) compared with that in nontreated mice and correlated well with ex vivo P-selec

129 significantly different between treated and nontreated mice at any time.

130 Molecular imaging in nontreated mice detected a 2-fold increase in P-selectin

131 same number of splenic dendritic cells from nontreated mice did not confer resistance to burn wound

132 All nontreated mice died, with a median survival of 16 d.

133 Unlike F4/80(+) APCs from nontreated mice, F4/80(+) APCs from RLB mice were unable

134 plasmic localization of CAR in the livers of nontreated mice, indicating that CAR translocates into n

135 gastric H. pylori colonization compared with nontreated mice.

136 ptake of (64)Cu-ATSM by tumors compared with nontreated mice.

137 ntly higher (18)F-FDOPA uptake than those in nontreated mice.

138 ur after the last AP challenge compared with nontreated mice.

139 oke, in mice subjected to osmotherapy and in nontreated mice.

140 rom treated microchimeric mice compared with nontreated microchimeric or with treated nonmicrochimeri

141 rval [CI], 1%-25%) and 16 of 37 infants with nontreated mothers (43%; 95% CI, 27%-59%) presented with

142 eated mothers did not differ from fetuses of nontreated mothers according to mother's age, gestationa

143 nal length in (+)-pentazocine-treated versus nontreated mutant mice.

144 Suspensions of treated and nontreated mycobacteria could be easily differentiated a

145 vided into five groups: sham, noninjured and nontreated (n = 6); control, injured and aerosolized wit

146 ed into two trauma groups, treated (N=7) and nontreated (N=8) animals.

147 d into three study groups: sham (noninjured, nontreated, n = 6); control (injured, treated with salin

148 ntrast to intermediate inhibitory effects in nontreated neutrophils, T. gondii induced a complete blo

149 TFII-I remains predominantly nuclear in both nontreated NIH 3T3 cells and cells treated with thapsiga

150 se tolerance tests (compared with those of 7 nontreated, nontransplanted mice with streptozotocin-ind

151 only observed in diseased mice, but also in nontreated NSG controls.

152 ore IL-2 and IFN-gamma than lymphocytes from nontreated or control-peptide-treated mice upon restimul

153 ability of 1,25-dihydroxyvitamin D3-treated, nontreated, or cyclosporine (CsA)-treated mice to resist

154 onchial inflammation score (P < 0.0001) than nontreated OVA-obese mice.

155 61 +/- 2 vs. 145 +/- 7 mg/dl, treated versus nontreated; P < 0.0001) and lowered islet TAG content (3

156 .7 vs. 47.8 +/- 2.7 ng/islet, treated versus nontreated; P < 0.0001) and preserved insulin mRNA level

157 +/- 16 vs. 388 +/- 36 mg/dl, treated versus nontreated; P < 0.0001) but did not prevent the rise in

158 atients were anticoagulated acutely, and the nontreated patient had recurrent, probably thromboemboli

159 ite treatment and one recurrent embolus in a nontreated patient.

160 in aspirin-treated diabetic patients versus nontreated patients (P < 0.001).

161 ulants was 13.6, in comparison with 27.3 for nontreated patients and 25.7 for patients receiving anti

162 agulants was 8.0, in comparison with 8.6 for nontreated patients and 5.3 for patients receiving antip

163 the CD4(+)CD90(+)/regulatory T cell ratio in nontreated patients compared with treated patients and h

164 Treated patients were less likely than nontreated patients to receive mechanical ventilation af

165 baseline creatinine (mg/dl) for treated and nontreated patients was 1.3 +/- 0.24 and 1.0 +/- 0.25, r

166 At 24 wk, creatinine of treated and nontreated patients was 1.5 +/- 0.34 and 4.9 +/- 2.4 (P

167 rine protein excretion (g/d) for treated and nontreated patients was 1.6 +/- 0.68 and 0.78 +/- 0.39,

168 Average baseline creatinine for treated and nontreated patients was 1.7 +/- 0.46 and 1.9 +/- 0.42, r

169 At 12 wk, creatinine for treated and nontreated patients was 2.0 +/- 1.0 and 9.2 +/- 2.0 (P =

170 eline 24-h protein excretion for treated and nontreated patients was 5.4 +/- 1.6 and 5.2 +/- 0.97 (P

171 ed patients who did not make antibody and in nontreated patients who did make antibody (6.0% vs. 5.7%

172 ured by enzyme-linked immunosorbent assay in nontreated patients with HeFH carrying a D206E (n = 237)

173 rate of CVS progression between treated and nontreated patients.

174 ted and 1.2 years (range, 0.9-8.8 years) for nontreated patients.

175 accuracy in localizing prostate cancer as in nontreated patients.

176 aily for a minimum of 2 yr as compared to 17 nontreated patients.

177 between the sorafenib-treated groups and the nontreated patients.

178 in the former group between ALP treated and nontreated patients.

179 e entire 70-day period of the study, whereas nontreated Pcp animals die 40-60 days after initiation o

180 3-6 months after medication start following nontreated periods.

181 lessened the rise in plasma TAG observed in nontreated rats (239 +/- 16 vs. 388 +/- 36 mg/dl, treate

182 erved morphological appearance than those in nontreated rats, as observed at different survival times

183 s 7 and 14 days postinjury, as compared with nontreated rats.

184 f survival (5.6+/-0.8 days) as compared with nontreated recipients (2.4+/-0.5 days).

185 n general low (2.5% and 2.0% for treated and nontreated, respectively) and similar across estimated g

186 rescence emission was checked in treated and nontreated samples of all the species, whereas histochem

187 e) that distinguished IL-6-stimulated versus nontreated samples.

188 ), whereas revascularized (0.5 +/- 0.21) and nontreated segments (-0.07 +/- 0.34) demonstrated noncon

189 Nontreated, sham and naive rats were also included.

190 Comparing treated and nontreated sides of the brain in 3 patients who underwen

191 >80%) compared with signals of contralateral nontreated sites at 4 h and at 1 d after PIT.

192 By flow cytometry, formalin-treated and nontreated spores of Encephalitozoon were identified to

193 n the most intense peaks of fluorescence for nontreated spores.

194 strategy, comparing outcomes for treated and nontreated students before and after the introduction of

195 inical trials have shown that, compared with nontreated subjects, rHuEPO-treated ICU patients will ha

196 We also studied recipients of nontreated syngenetic grafts.

197 nt with HRG compared to its level in control nontreated T47D cells.

198 ed Ca(2+) transients and decay compared with nontreated TAC hearts.

199 As compared to a frozen nontreated tissue sample, the liposome preparation proto

200 225 (9.84 +/- 2.51 %ID/g; P = 0.029) than in nontreated tumors (6.14 +/- 0.67 %ID/g), resulting in en

201 stoperative staging classifications used for nontreated tumors may not accurately predict patient pro

202 from both TRAIL receptor agonist-treated and nontreated tumors were found to be resistant to TRAIL-in

203 no significant changes were demonstrated in nontreated tumors.

204 as 0.75 (95% confidence interval, 0.71-0.79; nontreated used as reference).

205 ve statistics were obtained from treated and nontreated uterine tissue before and after treatment and

206 betaAR antagonist metoprolol (CSQ/betaARKct nontreated vs. CSQ/betaARKct metoprolol treated, 15 +/-

207 2 wk, 24-h protein excretion for treated and nontreated was 2.8 +/- 1.0 and 10.5 +/- 3.5 (P = 0.008).

208 ients (mean age 67 years; 44% women) treated/nontreated with statins.

209 in stromal cell proliferation compared with nontreated wounds, and a 2.5-fold increase compared with

210 5.6 to 9.5 days earlier than PRP-treated and nontreated wounds, respectively.